Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Cugene patents interleukin-2 variants

Jan. 15, 2020

As nanoparticles, vitamins fight sepsis

Jan. 15, 2020

Phase I/II data presented for the SIIPL-PCV vaccine candidate

Jan. 14, 2020

Moderna begins phase II study of CMV vaccine mRNA-1647

Jan. 13, 2020

Human CD83 CAR T cells for the prevention of GvHD and treatment of AML

Jan. 10, 2020

DBV reports data from open-label extension study of Viaskin Peanut

Jan. 9, 2020

CureVac reports interim phase I data on prophylactic mRNA-based rabies vaccine CV-7202

Jan. 8, 2020

Galapagos synthesizes SIK1, SIK2 and SIK3 inhibitors

Jan. 8, 2020

Phase III GRAVITAS-301 study of itacitinib in treatment-naive GvHD misses primary endpoint

Jan. 3, 2020

China NMPA approves Cecolin HPV16/18 vaccine

Jan. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...